Flavonoid compositions and methods of use

ABSTRACT

Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin. Also provided herein are methods for improving athletic performance, improving cardiovascular health, and aiding in immune response and methods of improving athletic performance, improving bone health, preventing fatigue, reducing recovery time after exercise, countering oxidative stress, and/or boosting energy.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.16/840,958, filed on Apr. 6, 2020, which is a continuation of U.S.patent application Ser. No. 16/596,468, filed on Oct. 8, 2019, which isa continuation of U.S. patent application Ser. No. 15/396,201, filedDec. 30, 2016, which issued as U.S. Pat. No. 10,441,621 on Oct. 15,2019, which is a continuation-in-part of U.S. patent application Ser.No. 15/272,826, filed Sep. 22, 2016, which issued as U.S. Pat. No.9,839,624 on Dec. 12, 2017, and which claims the benefit of priority toU.S. Provisional Patent Application No. 62/222,667, filed Sep. 23, 2015,the disclosure of each of which is incorporated by reference herein inits entirety.

FIELD OF THE DISCLOSURE

This disclosure pertains to flavonoid compositions and methods of usingsuch flavonoid compositions. More particularly, it pertains to flavonoidcompositions that are formulated for use by human and/or animalsubjects. The flavonoid compositions can include a flavonoid, forexample, the flavonoid quercetin and/or derivatives of quercetin, in aform that can be easily administered to a human and/or animal subject.The flavonoid compositions can also be configured to increase thebioavailability, absorption, distribution, metabolism, and/or excretionof quercetin. The flavonoid compositions can also comprise otheradditives to increase the bioavailability, absorption, distribution,metabolism, and/or excretion of quercetin.

BACKGROUND

Phytochemicals are chemicals produced by plants, and include tannins,lignins, and flavonoids. The largest and best studied polyphenols arethe flavonoids, with more than 8,000 identified and classified into atleast six subgroups: flavonols, flavones, flavanones, flavanols (andtheir oligomers, proanthocyanidins), anthocyanidins, and isoflavonoids(Table 1) (USDA Nutrient Data Laboratory. USDA Database for theFlavonoid Content of Selected Foods. (2007) Beltsville, Md.: U.S. Dept.of Agriculture). Only about 100 polyphenols are in foods humanstypically eat. Flavonoids are widely distributed in plants and functionas plant pigments, signaling molecules, and defenders against infectionand injury.

TABLE 1 Flavonoid Classification, Examples, and Sources FlavonoidSubgroup Specific Flavonoids Food Sources Flavonols Quercetin,kaempferol, onions, apples, leafy myricetin, isorhamnetin vegetables,berries Flavones Luteolin, apigenin parsley, hot peppers, celery,artichokes, spices Flavanones Hesperetin, naringenin, citrus fruits andcitrus eriodictyol juices Flavan-3-ols Catechins, tea, chocolate, treefruits, epigallocatechins, grape seed theaflavins AnthocyanidinsCyaniding, delphinidin, most berries, cowpeas malvidin, pelargonidin,peonidin, petunidin Isoflavones Daidzein, genistein, soybeans, soyfoodsglycitein

Dietary intake of flavonoids ranges from 50 to 800 mg/day depending onthe consumption of the food source containing various flavonoids. In theU.S., total flavonoid intake averages 251 mg/day (Chun Okla., Floegel A,Chung S J, et al. Estimation of antioxidant intakes from diet andsupplements in U.S. adults. J Nutr 2010; 140:317-24; the disclosure ofwhich is incorporated by reference herein in its entirety), and in Spain313 mg/day (Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventós R M, et al.Estimation of dietary sources and flavonoid intake in a Spanish adultpopulation (EPIC-Spain). J Am Diet Assoc 2010; 110:390-8; the disclosureof which is incorporated by reference herein in its entirety), withimportant sources including tea, citrus fruit and juice, beers and ales,wines, melon and berries, apples, onions, and bananas. Only about 29% ofindividuals consume tea on a given day, and without tea consumption, theflavonoid intake is closer to about 50 mg/day, reflecting the low intakeof fruits and vegetables by U.S. adults. The typical American is a lowconsumer of fruit (0.53 cups/1000 calories) and vegetables (0.77cups/1000 calories), well below the Healthy People 2020 goals of 0.90cups/1000 calories for fruit and 1.14 cups/1000 calories for vegetables.

A high intake of fruits and vegetables has been linked in numerousstudies to reduced risk of cardiovascular disease and various types ofcancer. The disease-reducing influence of fruits and vegetables may bedue in part to high levels of flavonoids (Hooper L, Kroon Pa., Rimm E B,et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: ameta-analysis of randomized controlled trials. Am J Clin Nutr 2008;88:38-50; Wang L, Lee I M, Zhang S M, et al. Dietary intake of selectedflavonols, flavones, and flavonoid-rich foods and risk of cancer inmiddle-aged and older women. Am J Clin Nutr 2009; 89:905-12; Zamora-RosR1, Rabassa M, Cherubini A, Urpi-Sarda M, Bandinelli S, Ferrucci L,Andres-Lacueva C. High concentrations of a urinary biomarker ofpolyphenol intake are associated with decreased mortality in olderadults. J Nutr. 2013; 143:1445-50). A 12-year study of 807 elderly menand women in Italy showed that those in the upper tertile for totalurinary polyphenol concentration (a proxy measure of fruit and vegetableintake) experienced a 30% reduction in all-cause mortality (Zamora-RosR1, Rabassa M, Cherubini A, Urpi-Sarda M, Bandinelli S, Ferrucci L,Andres-Lacueva C. High concentrations of a urinary biomarker ofpolyphenol intake are associated with decreased mortality in olderadults. J Nutr. 2013; 143:1445-50). These data strongly support that ahigh polyphenol intake is associated with extended longevity.

Many flavonoids possess strong anti-inflammatory, anti-viral,antioxidant, anti-obesity, and anti-carcinogenic properties when studiedin vitro using large doses of the purified form. Inflammation andoxidative stress are key mechanisms in the pathogenesis of certaindisease states, supporting the proposed strategy of increased flavonoidintake for prevention of cancer, diabetes mellitus, and cardiovasculardisease. However, results from randomized, double-blinded studies inhumans with large doses of purified flavonoids such as quercetin havebeen disappointing (Shanely R A, Knab A M, Nieman D C, et al. Quercetinsupplementation does not alter antioxidant status in humans. Free RadicRes 2010; 44:224-31). Flavonoids vary widely in bioavailability, andmost are poorly absorbed, undergo active efflux, and are extensivelyconjugated and metabolically transformed, all of which can affect theirbioactive capacities (Zhang L, Zuo Z, Lin G. Intestinal and hepaticglucuronidation of flavonoids. Mol Pharm 2007; 4:833-45). Despite lowbioavailability of the parent flavonoid, some of the in vivo metabolitesmay accumulate in tissues and produce bioactive influences, butconclusive human data are lacking. For example, animal data indicatethat quercetin metabolites accumulate in the vascular tissue and thereact as complementary antioxidants, with plasma albumin facilitating thetranslocation of quercetin metabolites to the vascular target (Terao J,Kawai Y, Murota K. Vegetable flavonoids and cardiovascular disease. AsiaPac J Clin Nutr 2008; 17(Suppl 1): 291-3).

There is a growing realization that bioactive influences of individualflavonoids are potentiated when mixed with other flavonoids (forexample, the flavonol quercetin with the flavanol epigallocatechin3-gallate (EGCG)) or included in a cocktail or extract of otherpolyphenols and nutrients (Lila Mass. From beans to berries and beyond:teamwork between plant chemicals for protection of optimal human health.Ann N Y Acad Sci 2007; 1114:372-80). Two or more flavonoids ingestedtogether may increase bioavailability and decrease elimination viacompetitive inhibition of glucuronide and sulfate conjugation in boththe intestine and liver, and by inhibiting efflux transporters such asP-glycoprotein, breast cancer resistance protein (BCRP), and multidrugresistance protein 2 (MRP2) (Kale A, Gawande S, Kotwal S, et al. Studieson the effects of oral administration of nutrient mixture, quercetin andred onions on the bioavailability of epigallocatechin gallate from greentea extract. Phytother Res 2010; 24 (Suppl 1):548-55).

The health-protective effects of plant foods are not produced by asingle component but rather complex mixtures of interacting molecules(Lila Mass. From beans to berries and beyond: teamwork between plantchemicals for protection of optimal human health. Ann N Y Acad Sci 2007;1114:372-80). The polyphenols and natural components provide amultifaceted defensive strategy for both plants and humans. Thus the“pharma” approach of using large doses of a single bioactive molecule isseldom successful in the application of nutrition to human health andperformance. Additionally, a metabolomics or nutrigenomics approach isneeded to improve the capacity of investigators to capture the complexand subtle influences of flavonoid supplements or flavonoid-richextracts, foods, and beverages on whole-body metabolism and physiology(Bakker G C, van Erk M J, Pellis L, et al. An antiinflammatory dietarymix modulates inflammation and oxidative and metabolic stress inoverweight men: a nutrigenomics approach. Am J Clin Nutr 2010;91:1044-59).

Quercetin is a flavonol compound that is found in many fruits andvegetables, such as red onions, capers, black plums, blueberries, andred applies. It has been reported to provide numerous health benefits tohumans that ingest the compound. These reported health benefits includeacting as a powerful antioxidant, improving athletic performance,improving cardiovascular health, and aiding in immune response. Somestudies have found that quercetin can reduce blood pressure and LDLcholesterol. Other studies have found that quercetin can increaseathletic performance.

Although quercetin can provide numerous benefits, many people may not beable to fully realize its benefits. For example, for many people theremay not be a convenient source of quercetin available to them. In somecases, some people may not enjoy the taste and/or flavors of naturalsources of quercetin. In other instances, some people may not be able toconsume sufficient amounts of quercetin to receive a beneficial effect.In other cases, some people may not be able to consume quercetin in amanner that makes the quercetin bioavailable.

Therefore, challenges currently exist in realizing the benefits ofquercetin. Accordingly, it would be an improvement in the art to providecompositions and methods to more fully realize the benefits ofquercetin.

SUMMARY

Flavonoid compositions and methods of use are disclosed herein. In someembodiments, the flavonoid composition can include a flavonoid incombination with one or more of an antioxidant, an anthocyanidin, astimulant, a lipid, ascorbic acid, an omega-3 fatty acid, and ascorbylpalmitate.

In some embodiments, the flavonoid includes quercetin or a derivative oranalogue thereof. In some embodiments, the flavonoid includes quercetin,aglycone quercetin, quercetin glycoside, isoquercetin, or combinationsthereof. In some embodiments, the antioxidant is green tea extract orepicatechin or a derivative thereof. In some embodiments, theantioxidant is epigallocatechin gallate (EGCG). In some embodiments, theanthocyanidin is a blueberry anthocyanidin. In some embodiments, thestimulant is caffeine. In some embodiments, the lipid is n3polyunsaturated fatty acid (N3-PUFA). In some embodiments, ascorbic acidis vitamin C. In some embodiments, the omega-3 fatty acid is an omega 3powder, which can include, for example eicosapentaenoic acid ordocosahexaenoic acid.

In some embodiments, the flavonoid composition can include about 10-500mg of flavonoid. In some embodiments, the flavonoid composition includesabout 52 mg of flavonoid. In some embodiments, the flavonoid compositionincludes about 10-500 mg of antioxidant. In some embodiments, theflavonoid composition includes about 90 mg EGCG. In some embodiments,the flavonoid composition includes about 10-500 mg of anthocyanidin. Insome embodiments, the flavonoid composition includes about 225 mganthocyanidin. In some embodiments, the flavonoid composition includesabout 10-500 mg of stimulant. In some embodiments, the flavonoidcomposition includes about 52 mg of stimulant. In some embodiments, theflavonoid composition includes about 10-500 mg of lipid. In someembodiments, the flavonoid composition includes about 100 mg of lipid.In some embodiments, the flavonoid composition includes about 10-500 mgof ascorbic acid. In some embodiments, the flavonoid compositionincludes about 100 mg of ascorbic acid. In some embodiments, theflavonoid composition includes about 10-500 mg of omega-3 fatty acid. Insome embodiments, the flavonoid composition includes about 100 mg ofomega-3 fatty acid. In some embodiments, the flavonoid compositionincludes about 10-500 mg of ascorbyl palmitate. In some embodiments, theflavonoid composition includes about 60 mg of ascorbyl palmitate.

In some embodiments the flavonoid composition can include about 34%(w/w) wild fresh blueberry extract, about 8% (w/w) caffeine, about 12%(w/w) vitamin C, about 14% (w/w) green tea extract, about 15% (w/w)omega-3 powder, about 8% (w/w) quercetin, and about 9% (w/w) ascorbylpalmitate. In other embodiments, the flavonoid composition includes anadditive configured to increase bioavailability of quercetin. In yetother embodiments, the flavonoid composition is administered to humansubjects to improve athletic performance.

In some embodiments is provided a flavonoid composition includingquercetin or an analogue or derivative thereof. In some embodiments, theanalogue or derivative of quercetin is aglycone quercetin, quercetinglycoside, isoquercetin, or combinations thereof. In some embodiments,the flavonoid composition further includes one or more of green teaextract, blueberry anthocyanidins, caffeine, N3-PUFA, vitamin C, omega-3powder, and ascorbyl palmitate.

In some embodiments, the composition is formulated as a chewable tablet,a chewable wafer, a capsule, a swallowable tablet, a stick pack, apowder sachet, gummi chews, tub and scoop, or other formulation.

Accordingly, in some embodiments is a flavonoid composition, includingquercetin. In some embodiments, quercetin is aglycone quercetin,quercetin glycoside, or isoquercetin. In some embodiments, the flavonoidcomposition includes green tea extract, blueberry anthocyanidins,caffeine, or N3-PUFA.

In some embodiments is provided a flavonoid composition, including 33.9%(w/w) blueberry extract; 7.9% (w/w) caffeine; 12.6% (w/w) vitamin C;13.6% (w/w) green tea extract; 15.1% (w/w) omega-3; 7.9% (w/w)quercetin; and 9.0% ascorbyl palmitate.

In some embodiments is provided an oral ingestible medicament, includingquercetin or an analogue or derivative thereof, epigallocatechin3-gallate (EGCG), blueberry anthocyanidins, caffeine, n-3polyunsaturated fatty acids (PUFA), and vitamin C.

In some embodiments, quercetin or an analogue or derivative thereof ispresent in an amount ranging from about 10-500 mg. In some embodiments,quercetin or an analogue or derivative thereof is present in an amountof about 100 mg. In some embodiments, quercetin or an analogue orderivative thereof is present in an amount of about 52 mg.

In some embodiments, quercetin or an analogue or derivative thereof ispresent in an amount of about 100 mg, EGCG is present in an amount ofabout 90-180 mg, blueberry anthocyanidins is present in an amount ofabout 120-240 mg, caffeine in present in an amount of about 100 mg,N3-PUFA is present in an amount of about 100 mg, and vitamin C ispresent in an amount of about 100 mg. In some embodiments, thecomposition or medicament includes ascorbyl palmitate.

In some embodiments, quercetin or an analogue or derivative thereof ispresent in an amount of about 52 mg, EGCG is present in an amount ofabout 90 mg, blueberry anthocyanidins is present in an amount of about225 mg, caffeine in present in an amount of about 52 mg, N3-PUFA ispresent in an amount of about 100 mg, vitamin C is present in an amountof about 50 mg, and ascorbyl palmitate is present in an amount of about60 mg.

In some embodiments, the oral ingestible medicament is administered to asubject two to four times each day. In some embodiments, the oralingestible medicament is a capsule, a chewable tablet, a stick pack, ora sachet.

In some embodiments are provided methods of using flavonoid compositionsfor the treatment, prevention, improvement, or amelioration of adisorder, disease or disease state. In some embodiments, the disorder,disease or disease state is a heart disease, diabetes, hypertension,allergic reactions, asthma, arthritis, cancer, prostate diseases, andoxidative stress. In some embodiments are provided methods of usingflavonoid compositions for the improvement of health or performance,including the improvement of athletic performance, improved bone health,strengthened immune response, prevention of fatigue, reduction inrecovery time following exercise, and for boosting energy. In someembodiments, the flavonoid compositions improve performance byincreasing mitochondrial biogenesis, increasing endurance, increasingstrength, and/or increasing performance. In some embodiments, theflavonoid compositions are administered to a subject before, during,and/or after exercise.

Accordingly, in some embodiments is provided a method for improvinghealth or performance in a subject. In some embodiments, the methodincludes administering to the subject an oral ingestible medicament orflavonoid composition as described herein.

In some embodiments is provided method for treating, ameliorating, orimproving a disorder in a subject, or improving the performance of asubject, includes administering to the subject an oral ingestiblemedicament or flavonoid composition as described herein.

In some embodiments, the disorder is heart disease, diabetes,hypertension, allergic reactions, asthma, arthritis, cancer, prostatediseases, and oxidative stress, or combinations thereof.

In some embodiments, the performance of the subject includes improvementin one or more of athletic performance, bone health, immune response,recovery time after exercise, oxidative stress, and energy.

In some embodiments, administration of an oral ingestible medicament orflavonoid composition as described herein increases the total urinaryphenolic concentration, the dietary flavonoid intake, the dietaryanthocyanin, the dietary EGCG, or the dietary quercetin. In someembodiments, administration of an oral ingestible medicament orflavonoid composition as described herein reduces the risk of mortality,neurodegenerative diseases, weight gain, systemic inflammation,oxidative stress, diabetes, cardiovascular disease, hypertension, oracute respiratory illness. In some embodiments, administration of anoral ingestible medicament or flavonoid composition as described hereinimproves colon health. In some embodiments, administration of an oralingestible medicament or flavonoid composition as described hereinimproves colon microbiome.

Some embodiments herein relate to a chewable tablet including quercetin,bilberry extract, green tea leaf extract, and one or more of vitamin C,caffeine, or omega 3 fatty acids. In some embodiments herein relate to achewable tablet including vitamin C, wild bilberry fruit extract, greentea leaf extract, quercetin aglycone, caffeine, and omega 3 fatty acids.In some embodiments, vitamin C is present as ascorbyl palmitate. In someembodiments, vitamin C is present in an amount of about 100 mg. In someembodiments, the wild bilberry fruit extract comprises about 25% totalanthocyanins. In some embodiments, the green tea leaf extract comprisesabout 50% epigallocatechin 3-gallate (EGCG). In some embodiments, theomega 3 fatty acids comprise n3 polyunsaturated fatty acids (n3-PUFA).In some embodiments, the n3-PUFA is present in an amount of about 60 mg.In some embodiments, the n3-PUFA comprises docosahexaenoic acid andeicosapentaenoic acid. In some embodiments, the docosahexaenoic acid ispresent in an amount of about 24 mg. In some embodiments, theeicosapentaenoic acid is present in an amount of about 36 mg. In someembodiments, the caffeine is present in an amount of about 107 mg. Insome embodiments, the composition comprises about 329 mg of totalflavonoids in aglycone form. In some embodiments, the tablet furtherincludes one or more of sugar, natural and artificial flavors, cellulosegum, sucralose, bamboo whole plant extract, guar gum, xanthan gum,citric acid, malic acid, or L-tartaric acid. In some embodiments,vitamin C is present in an amount of about 100 mg, the omega 3 fattyacids are present in an amount of about 60 mg, the caffeine is presentin an amount of about 107 mg, and total flavonoids are present in anamount of about 329 mg. In some embodiments, the chewable tablet isadministered to a subject at a dose of two tablets twice daily. In someembodiments, the chewable tablet is administered to a subject prior to ameal.

Some embodiments relate to a method of improving flavonoidbioavailability and bioactivity in a subject. In some embodiments, themethod includes administering the chewable tablet as described herein tothe subject. In some embodiments, the total flavonoid intake isincreased.

Some embodiments relate to a method of increasing gut-derived phenolicsin a subject. In some embodiments, the method includes administering achewable tablet as described herein to the subject. In some embodiments,increased gut-derived phenolics include one or more of1,2,3-benzenetriol sulfate, 3-methoxycatechol sulfate,3-(3-hydroxyphenyl)propanoic acid sulfate, 3-hydroxyhippurate, or4-methylcatechol sulfate.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to describe the manner in which the above-recited and otheradvantages and features of the invention can be obtained, a moreparticular description will be rendered by reference to specificembodiments thereof which are illustrated in the appended drawings.Understanding that these drawings depict only typical embodiments andare not therefore to be considered to be limiting of its scope, theinvention will be described and explained with additional specificityand detail through the use of the accompanying drawings in which:

FIG. 1 illustrates a chemical drawing of an exemplary quercetin, whereinthe quercetin is aglycone quercetin.

FIG. 2 illustrates a chemical drawing an exemplary quercetin4′-glucoside.

FIG. 3 illustrates a chemical drawing of an exemplary quercetin3,4′-diglucoside.

FIG. 4 depicts an exemplary chromatography profile of wild blueberryextract, identifying exemplary anthocyanidins that may be present inwild blueberry extracts.

FIGS. 5A-5D graphically depict the concentration of metabolites in thetest group (left; administered a flavonoid composition) and the controlgroup (right; administered placebo) prior to and at 12-weeks ofadministration of a flavonoid composition or placebo. FIG. 5A depictsdietary flavonoid concentration. FIG. 5B depicts dietaryepigallocatechin 3-gallate (EGCG) concentration. FIG. 5C depicts dietaryanthocyanin concentration. FIG. 5D depicts dietary quercetinconcentration.

FIG. 6 graphically depicts the urinary phenolic concentration in thetest group (left; administered a flavonoid composition) compared to thecontrol group (right; administered placebo). Samples were obtainedpre-study, at four weeks, and at 12 weeks.

FIG. 7 depicts an exemplary chromatography profile of the flavonoids andcaffeine in one embodiment of a flavonoid composition, recorded at 280nm. Compounds were quantified from standard curves created withreference compounds.

FIG. 8 graphically depicts the total flavonoid intake increase, frompre-study to 12-weeks. The bars on the left represent flavonoidsupplementation, and the bars on the right represents placebo. Totalflavonoid intake increased 217% as a result of taking the tablet(containing 329 mg of total flavonoid) compared to placebo. The p valueover the flavonoid group bars represent the post-hoc analysis comparingthe change from pre-study between groups.

FIG. 9 graphically depicts the change in plasma caffeine levels after12-weeks of supplementation with one embodiment of a flavonoidcomposition. Plasma caffeine levels are depicted from left to right as:flavonoid pre-study; flavonoid after 12 weeks; placebo pre-study; andplacebo after 12 weeks.

FIGS. 10A-10C graphically depict the increases in gut-derived phenolicsin the subject having flavonoid supplementation compared to placebo.FIG. 10A shows the increases of 3-methoxycatechol sulfate (p=0.015).FIG. 10B shows the increases in 3-(3-hydroxyphenyl)propionic acidsulfate (p=0.050). FIG. 10C shows the increases in 1,2,3-benzenetriolsulfate (p=0.030). All graphs show increases of gut-derived phenolicsfrom left to right as: flavonoid pre-study; flavonoid after 12 weeks;placebo pre-study; and placebo after 12 weeks.

DETAILED DESCRIPTION

In some embodiments, the present application discloses flavonoidcompositions and methods of using these flavonoid compositions. In otherembodiments, the compositions and methods comprise compositionscontaining quercetin. In yet other embodiments, the methods comprisemethods of preparing compositions containing quercetin. In someinstances, the methods comprise methods of administering a compositionof quercetin to a human and/or animal subject. The compositioncontaining quercetin can comprise any effective amount of quercetin. Thecomposition containing quercetin can also comprise one or more additivecomponents configured to modulate the bioavailability, absorption,distribution, metabolism, and/or excretion of quercetin to increase atherapeutic effect of quercetin on the human and/or animal subject.

The term “subject” includes animals (for example, mammals, for example,cats, dogs, horses, pigs, cows, sheep, rodents, rabbits, squirrels,camels, bears, primates (for example, chimpanzees, gorillas, andhumans)). It also includes transgenic animal models.

In some embodiments, polyphenols, flavonoids, flavonols, and quercetinare reported to provide health benefits. As described herein,polyphenols, flavonoids, flavonols, and quercetin are shown to preventand/or treat heart disease, to help treat diabetes, to prevent and/ortreat hypertension, to treat allergic reactions, to treat asthma, totreat arthritis, to prevent and/or treat cancer, to alleviate prostateproblems, to improve athletic performance, to improve bone health, tostrengthen immune response, to prevent fatigue, to reduce recovery timeafter exercise, to counter oxidative stress, and/or to boost energy.

In some embodiments, polyphenols, flavonoids, flavonols, and quercetinare administered to help athletes before, during, and/or after exercise.Polyphenols, flavonoids, flavonols, and quercetin can help athletes byincreasing mitochondrial biogenesis, increasing endurance, and/orincreasing performance.

As used herein, the term “polyphenols” refers to a compound containingmore than one phenolic hydroxyl group. Polyphenols are a structuralclass of mainly natural, but also synthetic or semisynthetic organicchemicals characterized by the presence of large multiples of phenolstructural units. Polyphenols are a classification of colorful phenolicorganic compounds found in plants. As described herein, a high dietaryintake of polyphenols reduce the risk for one or more of mortality,neurodegenerative diseases, weight gain, systemic inflammation andoxidative stress, diabetes, cardiovascular disease, hypertension, oracute respiratory illness.

As used herein, the term “flavonoids” refers to a group of plantmetabolites that provide health benefits through cell signaling pathwaysand antioxidant effects. Flavonoids are polyphenolic moleculescontaining 15 carbon atoms and are soluble in water. Flavonoids are asubgroup within the polyphenols and function as natural antioxidants.

The flavonoid subgroup can be divided into six smaller groups includingflavonols. As used herein, the term “flavonol” refers to phytochemicalcompounds found in high concentrations in a variety of plant-based foodsand beverages. Based on their structure, they are classified asflavonoids and include the following compounds: quercetin, kaempferol,and myricetin.

As used herein, the term “quercetin” refers to a yellow crystallinepigment present in plants, and is used as a food supplement to reduceallergic responses or to boost immunity. Quercetin belongs to theflavonol group and can be found in a wide variety of fruits andvegetables. Quercetin can be found at least in the following fruits andvegetables: capers, lovage, dock like sorrel, radish leaves, carobfiber, dill, cilantro, Hungarian wax pepper, fennel leaves, red onion,radicchio, watercress, buckwheat, kale, chokeberry, cranberry,lingonberry, black plums, cow peas, sweet potato, blueberry, seabuckthorn berry, rowanberry, crowberry, prickly pear cactus fruits, redapples, broccoli, bilberry, tomatoes, black tea, and green tea. In someembodiments, pure quercetin may be extracted from the flowering genus ofplants, Uncaria.

In some embodiments, flavonoids are derived from plant extracts,including from blueberry or bilberry fruit extracts. In someembodiments, flavonoids are derived from the genus of plants, Vaccinium.

In some embodiments, quercetin can refer to aglycone quercetin (orquercetin aglycone). FIG. 1 illustrates embodiments of aglyconequercetin. Aglycone quercetin can refer to the quercetin backbonewithout any bound glucosyl or polysaccharide groups. Aglycone quercetincan also be referred to as2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one. Aglyconequercetin can also be referred to as one or more of sophoretin, meletin,quercetin, xanthaurine, quercetol, quertine, and/or flavin meletin.

In some embodiments, quercetin refers to quercetin glucosides. Naturallyoccurring forms of quercetin can include quercetin glycosides. Quercetinglycosides can include rutin, (for example, rutoside, sophorin, andquercetin-3-O-rutinoside). Quercetin glycoside can also includequercitrin, which is a 3-O-a-L-rhamnoside. Quercetin glycoside can alsoinclude guaijaverin, which is a 3-O-arabinoside. Quercetin glycoside canalso include hyperoside, which is a 3-O-galactoside. Quercetin glycosidecan also include isoquercetin, which is a 3-O-glucoside. Quercetinglycoside can also include spiraeoside, which is a 4′-O-glucoside.Quercetin glycoside can also include miquelianin, which is a quercetin3-O-B-d-glucuronopyranoside. FIG. 2 illustrates a quercetin glycoside,quercetin 4′-glucoside. FIG. 3 illustrates a quercetin glycoside,quercetin 3,4′-diglucoside.

In some embodiments, quercetin comprises any aglycone quercetin, anyquercetin glycoside, and/or any quercetin derivative. Quercetin can bederived from any appropriate plant-based source. Quercetin can compriseany plant-based extract that is enriched in any aglycone quercetin, anyquercetin glycoside, and/or any quercetin derivative. Quercetin can beextracted, isolated, and/or enriched by any appropriate methods as knownin the art. Quercetin can comprise a mixture further comprising one ormore of polyphenols, flavonoids, and/or flavonols.

In some embodiments, quercetin can have a generally low bioavailabilityupon ingestion. The generally low bioavailability can possibly be due tolow absorption, rapid metabolism, and/or rapid elimination afteringestion. In other embodiments, absorption can be affected bydifferences in glycosylation, the makeup of the food matrix thatcontains the quercetin, and/or co-consumption of other food componentssuch as fiber. In yet other embodiments, quercetin bioavailabilityincreases with co-ingestion of other food components such as fats. Insome cases, pure quercetin aglycone is absorbed differently thanquercetin glycosides. In other cases, quercetin glycosides such asisoquercetin are more completely absorbed than quercetin aglycone. Insome instances, simultaneous ingestion of quercetin with additives suchas vitamin C, folate, and/or additional flavonoids improves thebioavailability of quercetin. Quercetin has a half-life of about 3.5-11hours, and accumulates in the lungs, kidneys, heart, and liver.

The term “bioavailability” includes, generally, the degree to which adrug or other substance becomes available to a subject followingingestion, administration, or exposure. In one embodiment, for example,the bioavailability of the quercetin compounds may be thebioavailability to a particular target tissue. For example, in anembodiment, the particular target tissue may require traversal of thestomach or the small intestines, therefore the bioavailability data maybe obtained from this particular target tissue.

The term “bioactive” includes, generally, to a property orcharacteristic of a substance, molecule, agent, or formulation orcomponent thereof, having a biological effect.

In some embodiments, the bioavailability and bioactive influences ofindividual flavonoids are potentiated when mixed with other flavonoidsor included with other polyphenols, nutrients, and omega-3 fatty acids.In some embodiments, n3-PUFa enhances both the bioavailability andbioactive effects of the flavonoids and flavonoid formulations providedherein. In some embodiments, n3-PUFA enhances the bioavailability andbioactive effects of quercetin.

The majority of dietary polyphenol intake reaches the colon. Polyphenolsare subject to microbial degradation in the colon, convertingpolyphenols to simple phenols, and improving colon health andmicrobiome. Phenols can then be reabsorbed into the portal vein, whichcan be augmented with exercise, to the liver. In the liver, phenolsundergo phase II biotransformation. The product is then released intocirculation, where it exerts a beneficial bioactive effect before beingexcreted in the urine. As an example, the polyphenol, cyaniding, isconverted to hydroxybenzoic acid by microbial degradation in the colon.Hydroxybenzoic acid is converted to hippuric acid through phase-2conjugation. Hippuric acid is released into the bloodstream, and iseventually excreted in the urine. A high urine phenolic content reflectsa high diet intake of polyphenols, and is linked to 30% lower mortality.Furthermore, a high diet consumption of flavonoids is associated withreduced risk of mortality in older women of about 60%. In someembodiments, a flavonoid formulation can provide an increase in urinetotal phenolics and in gut-derived phenolic metabolites.

In some embodiments, the flavonoid composition comprises one or moreactive ingredients, including: 100 mg quercetin, quercetin analogueand/or derivative, or preferably isoquercetin, or combinations thereof(for example, at least about 50% each of quercetin and isoquercetin),90-180 mg epigallocatechin 3-gallate (EGCG) with green tea extract,120-240 mg blueberry anthocyanidins from extract, 100 mg caffeine, 100mg N3-PUFA (60 mg DHA, 40 mg EPA), and 100 mg vitamin C. In otherembodiments, the flavonoid composition comprises any other additive thatis effective for increasing the bioavailability of the quercetin.

In some embodiments, the flavonoid composition includes quercetinaglycone or an analogue or derivative thereof, green tea leaf extract(50% EGCG), bilberry fruit extracts (25% total anthocyanins), caffeine,n3-PUFA (a mixture of docosahexaenoic acid and eicosapentaenoic acid),and vitamin C (as ascorbyl acetate).

In some embodiments, the flavonoid composition includes a flavonoidother than or in addition to quercetin, for example, one or moreflavonoid as described in Table 1 or other flavonoid. Thus, theflavonoid composition can include one or more of quercetin, kaempferol,myricetin, isorhamnetin, luteolin, apigenin, hesperetin, naringenin,eriodictyol, catechins, epigallocatechins, theaflavins, cyaniding,delphinidin, malvidin, pelargonidin, peonidin, petunidin, daidzein,genistein, or glycitein. In some embodiments, the flavonoid is presentin an amount of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130,140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270,280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410,420, 430, 440, 450, 460, 470, 480, 490, or 500 mg or greater, or a valuewithin a range defined by any two of the aforementioned values. In someembodiments, the flavonoid is present in an amount of about 52 mg. Insome embodiments, the total flavonoids present in the composition is inan amount of about 329 mg.

In some embodiments, the flavonoid composition further comprises anantioxidant. As used herein, the term “antioxidant” refers broadly to amolecule that inhibits the oxidation of other molecules. In someembodiments, an antioxidant, as used herein, refers to green tea extractand its molecular components, which can include, for example,epigallocatechin (EGC), epicatechin gallate (ECG), epigallocatechingallate (EGCG), epicatechin (EC), and flavonoids, such as kaempferol,quercetin, and myricetin. In some embodiments, the antioxidant ispresent in an amount of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110,120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250,260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390,400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 mg or greater,or a value within a range defined by any two of the aforementionedvalues. In some embodiments, the antioxidant is present in an amount ofabout 90 mg. In some embodiments, the antioxidant is present as greentea leaf extract having 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45,50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% EGCG. In someembodiments, the antioxidant is present as green tea leaf extract havingabout 50% EGCG.

In some embodiments, the flavonoid composition includes an anthocyanin.As used herein, the term “anthocyanin” refers to a class of flavonoidsobtained from tissues of plants, including from blueberry or bilberryfruit extracts. In some embodiments, the anthocyanin is present in anamount of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140,150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280,290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420,430, 440, 450, 460, 470, 480, 490, or 500 mg or greater, or a valuewithin a range defined by any two of the aforementioned values. In someembodiments, the anthocyanin is present in an amount of about 225 mg. Insome embodiments, the anthocyanin is a bilberry fruit extract having anamount of 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,70, 75, 80, 85, 90, 95, or 100% total anthocyanin, or a percentagewithin a range defined by any two of the aforementioned percentages. Insome embodiments, bilberry fruits extract is present having an amount ofabout 25% total anthocyanins.

In some embodiments, the flavonoid composition further comprises ananthocyanidin. As used herein, the term “anthocyanidin” refers to aplant pigment from a plant extract, and is a sugar-free counterpart ofanthocyanins. In some embodiments, an anthocyanidin can be obtained froma plant, including from blueberry extracts. In some embodiments,anthocyanidins include, for example, apigeninidin, aurantinidin,capensinidin, cyanidin, delphinidin, europinidin, hirsutidin,luteolinidin, malvidin, pelargonidin, peonidin, petunidin, pulchellidin,rosinidin, or triacetin, or combinations thereof. In some embodiments,the anthocyanidin is present in an amount of 10, 20, 30, 40, 50, 60, 70,80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220,230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360,370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500mg or greater, or a value within a range defined by any two of theaforementioned values. In some embodiments, the anthocyanidin is presentin an amount of about 225 mg.

In some embodiments, the flavonoid composition further comprises astimulant. As used herein, the term “stimulant” refers topharmaceutically active compounds that temporarily increase the rate ofbody functions. Stimulants can include, for example, amineptine,amiphenazole, amphetamines, bromantan, caffeine, carphedon, cocaine,ephedrines, fencamfamine, mesocarb, pentylentetrazol, pipradol,salbutamol, salmeterol, terbutaline, and related substances. In someembodiments, the stimulant is present in an amount of 10, 20, 30, 40,50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190,200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330,340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470,480, 490, or 500 mg or greater, or a value within a range defined by anytwo of the aforementioned values. In some embodiments, the stimulant ispresent in an amount of about 52 mg. In some embodiments, the stimulantis present in an amount of about 107 mg.

In some embodiments, the flavonoid composition further comprises alipid. As used herein, the term “lipid” refers to fatty acids andderivatives thereof, as well as substances related biosynthetically orfunctionally to such compounds. In some embodiments, lipids refers to n3polyunsaturated fatty acids (N3-PUFA or n3-PUFA). In some embodiments,the lipid is present in an amount of 10, 20, 30, 40, 50, 60, 70, 80, 90,100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230,240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370,380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 mg orgreater, or a value within a range defined by any two of theaforementioned values. In some embodiments, the lipid is present in anamount of about 100 mg. In some embodiments, the lipid is present in anamount of about 60 mg. In some embodiments, the lipid is present asn3-PUFA. In some embodiments, n3-PUFA is a combination ofdocosahexaenoic acid and eicosapentaenoic acid. In some embodiments,docosahexaenoic acid is present in an amount of about 24 mg andeicosapentaenoic acid is present in an amount of about 36 mg.

In some embodiments, the flavonoid composition further comprisesascorbic acid. Ascorbic acid refers to one form of vitamin C, andderivatives or analogues thereof. In some embodiments, ascorbic acid ispresent in an amount of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110,120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250,260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390,400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 mg or greater,or a value within a range defined by any two of the aforementionedvalues. In some embodiments, ascorbic acid is present in an amount ofabout 50 mg. In some embodiments, ascorbic acid is present as vitamin Cin an amount of about 100 mg.

In some embodiments, the flavonoid composition further comprises omega 3fatty acids. Omega 3 fatty acids can be prepared in powder formulationsand can include, for example, eicosapentaenoic acid, docosahexaenoicacid, linolenic acid, hexadecatrienoic acid, stearidonic acid,eicosatrienoic acid, eicosatetraenoic acid, heneicosapentaenoic acid,docosapentaenoic acid, tetracosapentaenoic acid, or tetracosahexaenoicacid, or analogues or derivatives thereof, or combinations thereof. Insome embodiments, the omega 3 fatty acid is present in an amount of 10,20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170,180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310,320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450,460, 470, 480, 490, or 500 mg or greater, or a value within a rangedefined by any two of the aforementioned values. In some embodiments,the omega 3 fatty acid is present in an amount of about 100 mg.

In some embodiments, the flavonoid composition further comprisesascorbyl palmitate. In some embodiments, ascorbyl palmitate is presentin an amount of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130,140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270,280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410,420, 430, 440, 450, 460, 470, 480, 490, or 500 mg or greater, or a valuewithin a range defined by any two of the aforementioned values. In someembodiments, the ascorbyl palmitate is present in an amount of about 60mg. In some embodiments, ascorbyl palmitate is formed from ascorbic acidand palmitic acid creating a fat-soluble form of vitamin C. In someembodiments, ascorbyl palmitate is present in an amount of about 100 mg.

Accordingly, in some embodiments, the flavonoid composition includes aflavonoid (10-500 mg, for example 52 mg), an antioxidant (10-500 mg, forexample 90 mg), an anthocyanidin (10-500 mg, for example 225 mg), astimulant (10-500 mg, for example 52 mg), a lipid (10-500 mg, forexample, 100 mg), ascorbic acid (10-500 mg, for example, 50 mg), anomega 3 fatty acid (10-500 mg, for example, 100 mg), and ascorbylpalmitate (10-500 mg, for example, 60 mg). The compositions may have oneor more of the aforementioned components in a range of quantities. Thequantities vary depending on the circumstance, requirements, or purposeof the specific formulation. Thus, for example, one formulation mayrequire a greater quantity of any one or more component than a differentformulation. Thus, the provided quantities are given by way of exampleonly and are not intended to be limiting in scope.

In some embodiments, the additive is used to enhance bioavailability ofthe flavonoid or of quercetin, and thus the additive is abioavailability enhancing agent. The term “bioavailability enhancingagent” includes agents that, when administered in combination withquercetin, increase the availability of the quercetin compound in thesubject. Suitable bioavailability enhancing agents include, for example,charge masking compounds, solubilizing compounds, reducing compounds,stabilizing compounds, lubricating compounds, enteric coatings,permeability enhancing compounds, or combinations thereof. Thus, thebioavailability enhancing agent can include, for example, polysorbate 80(TWEEN-80), ethylenediaminetetraacetic acid (EDTA), sodium bisulfite,octanol, oil, ethanol, calcium chloride, or silicon dioxide, orcombinations thereof. In some embodiments, the formulations providedherein enhance the bioavailability and the bioactivity effects ofquercetin.

In some embodiments is provided a therapeutic composition comprising atherapeutically effective amount of a quercetin compound in combinationwith a bioavailability enhancing agent and a pharmaceutically acceptablecarrier for administration of said quercetin compound to the intestinaltract. The bioavailability enhancing agent and the quercetin compoundmay be administered concurrently in separate or in the same therapeuticcomposition.

The language “effective amount” of the quercetin compound is that amountnecessary or sufficient to treat a subject, or to provide improvement,benefit, or enhancement to health or performance. The effective amountcan vary depending on such factors as the size and weight of thesubject, the type of result or outcome, or the particular quercetincompound. For example, the choice of the quercetin compound can affectwhat constitutes an “effective amount”. One of ordinary skill in the artwould be able to study the aforementioned factors and make thedetermination regarding the effective amount of the quercetin compoundwithout undue experimentation.

In yet other embodiments, the flavonoid composition can comprise a pH ofabout 3 to about 4 to increase flavonoid stability. In some embodiments,the flavonoid composition comprises active ingredients configured to actsynergistically to increase the bioavailability of quercetin. Forexample, vitamin C can act to increase the bioavailability of quercetin.

In some embodiments, the flavonoid composition comprises one or moreactive ingredients, including: about 16% (w/w) quercetin or an analogueor derivative thereof, or a combination thereof, including, for example,isoquercetin (or 50% each), about 15% to about 30% EGCG with green teaextract, about 20-40% (w/w) blueberry anthocyanidins from extract, about16% (w/w) caffeine, about 16% (w/w) 100 mg N3-PUFA (60% DHA, 40% EPA),and about 16% vitamin C.

In some embodiments, the flavonoid composition comprises one or morenon-active ingredients. In other embodiments, the non-active ingredientsare configured to act as an inert carrier for the active ingredients. Inyet other embodiments, the non-active ingredients can include one ormore of: Domino Sugar Direct Compressible (Batory); Dextrose(Agglomerated); Flavor (Masking Type N&A) FCI 58002155; Flavor (Nat.Birthday Cake) Carmi 25193; Flavor (FLAVOR SWEET A NATURAL FLAVOR)—FCI#40018125; Flavor (Vanilla N&A) Gold Coast #310119; Natural BitternessSuppressor; Flavor (RASPBERRY—NAT & ART)—FCI #79028114; Natural BambooSilica; Sucralose; Flavor (Blueberry N&A)—FCI #12001135; Citric AcidAnhydrous; Flavor (Acai—N&A) FCI #10001154; DL-Malic Acid, L-TartaricAcid, natural and artificial flavors, cellulose gum, bamboo whole plantextract, guar gum, or xanthan gum.

In some embodiments, the flavonoid composition comprises a form that isconfigured to be readily ingested by a human and/or animal subject. Forexample, the flavonoid composition can comprise a chew tablet that canbe readily chewed to be ingested. In other cases, the flavonoidcomposition comprises a pill or tablet. In other instances, theflavonoid composition comprises a gummy chew. In yet other cases, theflavonoid composition can comprise a dissolvable strip or a thickgoo-like form. In other embodiments, the flavonoid composition isconfigured as a slow-release or extended-release formulation.

In some embodiments, the flavonoid composition is configured as a chewtablet and is configured to be consumed with an aqueous carbohydratesource. The aqueous carbohydrate source can comprise a 2:1 glucose tofructose ratio. In other embodiments, the flavonoid composition isconfigured as a single chew tablet that comprises 100 mg quercetin orpreferably isoquercetin (or 50% each), 90-180 mg EGCG with green teaextract, 120-240 mg blueberry anthocyanidins from extract, 100 mgcaffeine, 100 mg N3-PUFA (60 mg DHA, 40 mg EPA), and 100 mg vitamin C.Two to four of these single chew tablets can be administered to asubject per day. In yet other embodiments, the described single chewtablets act as a substitute for non-steroidal anti-inflammatory drugs(NSAIDs). In some embodiments, each tablet includes from 10-500 mg offlavonoid. In some embodiments, each tablet includes 10, 20, 30, 40, 50,60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450,or 500 mg of flavonoid or greater, or an amount within a ranged definedby any two of the aforementioned values. In some embodiments, eachtablet includes about 70 mg of flavonoid. In some embodiments, fourtablets are administered daily. In some embodiments, the total dailyadministration includes about 280 mg of flavonoid. In some embodiments,two tablets are taken at a given time, twice daily.

Flavors are additives that give food a particular taste or smell, andmay be derived from naturally occurring ingredients or preparedsynthetically. In some embodiments, the flavor may include chocolate,vanilla, cola, coffee, latte, cappuccino, butterscotch, almond, mint,peach, grape, pear, passion fruit, pineapple, banana or banana puree,apricot, citrus, orange, lemon, grapefruit, apple, cranberry, tomato,mango, papaya, lime, tangerine, cherry, blueberry, strawberry,raspberry, coconut, carrot and/or mixtures thereof.

As used herein, the term “treatment” refers to an intervention made inresponse to a disease, disorder or physiological condition manifested bya subject, particularly a subject suffering from one or more of adisorder, disease or disease state. In some embodiments, the disorder,disease or disease state is a heart disease, diabetes, hypertension,allergic reactions, asthma, arthritis, cancer, prostate diseases, andoxidative stress. In some embodiments, the treatment refers to theimprovement of health or performance, including the improvement ofathletic performance, improved bone health, strengthened immuneresponse, prevention of fatigue, reduction in recovery time followingexercise, and for boosting energy. The aim of treatment may include, butis not limited to, one or more of the alleviation or prevention ofsymptoms, slowing or stopping the progression or worsening of a disease,disorder, or condition and the remission of the disease, disorder orcondition. In some embodiments, “treatment” refers to both therapeutictreatment and prophylactic or preventative measures. Those in need oftreatment include those already affected by a disease or disorder orundesired physiological condition as well as those in which the diseaseor disorder or undesired physiological condition is to be prevented. Forexample, in some embodiments, treatments reduce, alleviate, or eradicatethe symptom(s) of the disease(s). In some embodiments, treatment canrefer to enhancement of secondary effects of the disease, includingenhancement or improvement of athletic performance. As used herein, theterm “prevention” refers to any activity that reduces the burden of theindividual later expressing disease symptoms. This can take place atprimary, secondary and/or tertiary prevention levels, wherein: a)primary prevention avoids the development ofsymptoms/disorder/condition; b) secondary prevention activities areaimed at early stages of the condition/disorder/symptom treatment,thereby increasing opportunities for interventions to preventprogression of the condition/disorder/symptom and emergence of symptoms;and c) tertiary prevention reduces the negative impact of an alreadyestablished condition/disorder/symptom by, for example, restoringfunction and/or reducing any condition/disorder/symptom or relatedcomplications. In some embodiments, the flavonoid formulations describedherein have anticancer effects. In some embodiments, the combination ofquercetin, green tea extract, vitamin C, and other micronutrients showimproved anticancer efficacy in cell culture.

“Pharmaceutically acceptable” carriers are ones which are nontoxic tothe cell or mammal being exposed thereto at the dosages andconcentrations employed. “Pharmaceutically acceptable” carriers can be,but not limited to, organic or inorganic, solid or liquid excipientswhich is suitable for the selected mode of application such as oralapplication, and administered in the form of a conventional therapeuticpreparation, such as solid such as tablets, granules, powders, capsules,and liquid such as solution, emulsion, suspension and the like. Oftenthe physiologically acceptable carrier is an aqueous pH bufferedsolution such as phosphate buffer or citrate buffer. The physiologicallyacceptable carrier may also include, for example, one or more of thefollowing: antioxidants including ascorbic acid, low molecular weight(less than about 10 residues) polypeptides, proteins, such as serumalbumin, gelatin, immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone, amino acids, carbohydrates including glucose,mannose, or dextrins, chelating agents such as EDTA, sugar alcohols suchas mannitol or sorbitol, salt-forming counter ions such as sodium, andnonionic surfactants such as Tween™, polyethylene glycol (PEG), andPluronics™. Auxiliary, stabilizer, emulsifier, lubricant, binder, pHadjustor controller, isotonic agent and other conventional additives mayalso be added to the carriers. Pharmaceutically acceptable carrierincludes substances. capable of being coadministered with the quercetincompound(s), and which allow both to perform their intended function.

The pharmaceutically acceptable or appropriate carrier may include othercompounds known to be beneficial to an impaired situation of the GItract, (for example, antioxidants, such as Vitamin C, Vitamin E,Selenium or Zinc); or a food composition. The food composition can be,but is not limited to, milk, yogurt, curd, cheese, fermented milks, milkbased fermented products, ice-creams, fermented cereal based products,milk based powders, infant formulae, tablets, liquid bacterialsuspensions, dried oral supplement, or wet oral supplement.

The articles “a” and “an” are used herein to refer to one or to morethan one (i.e., to at least one) of the grammatical object of thearticle. By way of example, “an element” means one element or more thanone element.

By “about” is meant a quantity, level, value, number, frequency,percentage, dimension, size, amount, weight or length that varies by asmuch as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a referencequantity, level, value, number, frequency, percentage, dimension, size,amount, weight or length.

Throughout this specification, unless the context requires otherwise,the words “comprise,” “comprises,” and “comprising” will be understoodto imply the inclusion of a stated step or element or group of steps orelements but not the exclusion of any other step or element or group ofsteps or elements.

By “consisting of” is meant including, and limited to, whatever followsthe phrase “consisting of” Thus, the phrase “consisting of” indicatesthat the listed elements are required or mandatory, and that no otherelements may be present. By “consisting essentially of” is meantincluding any elements listed after the phrase, and limited to otherelements that do not interfere with or contribute to the activity oraction specified in the disclosure for the listed elements. Thus, thephrase “consisting essentially of” indicates that the listed elementsare required or mandatory, but that other elements are optional and mayor may not be present depending upon whether or not they materiallyaffect the activity or action of the listed elements.

In certain embodiments, the “purity” of any given agent (for example,fulvate fraction, growth factor, etc.) in a composition may bespecifically defined. For instance, certain compositions may include,for example, an agent that is at least 80, 85, 90, 91, 92, 93, 94, 95,96, 97, 98, 99, or 100% pure, including all decimals in between, asmeasured, for example and by no means limiting, by high pressure liquidchromatography (HPLC), a well-known form of column chromatography usedfrequently in biochemistry and analytical chemistry to separate,identify, and quantify compounds.

The term “solubility” refers to the property of a polyphenol, flavonoid,flavonol, quercetin, or other agent provided herein to dissolve in aliquid solvent and form a homogeneous solution. Solubility is typicallyexpressed as a concentration, either by mass of solute per unit volumeof solvent (g of solute per kg of solvent, g per dL (100 mL), mg/mL,etc.), molarity, molality, mole fraction or other similar descriptionsof concentration. The maximum equilibrium amount of solute that candissolve per amount of solvent is the solubility of that solute in thatsolvent under the specified conditions, including temperature, pressure,pH, and the nature of the solvent. In certain embodiments, solubility ismeasured at physiological pH. In certain embodiments, solubility ismeasured in water or a physiological buffer such as PBS. In certainembodiments, solubility is measured in a biological fluid (solvent) suchas blood or serum. In certain embodiments, the temperature can be aboutroom temperature (for example, about 20, 21, 22, 23, 24, 25° C.) orabout body temperature (37° C.). In certain embodiments, an agent has asolubility of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8,0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 25, or 30 mg/mL at room temperature or at 37° C.

Therapeutic Compositions

In some embodiments, the active ingredients and mixtures of activeingredients may be used, for example, in therapeutic compositionscomprising a pharmaceutically acceptable carrier prepared for storageand subsequent administration. Also, some embodiments include use of theabove-described active ingredients with a pharmaceutically acceptablecarrier or diluent. Acceptable carriers or diluents for therapeutic useare well known in the pharmaceutical art, and are described, forexample, in Remington's Pharmaceutical Sciences, 18th Ed., MackPublishing Co., Easton, Pa. (1990), which is incorporated herein byreference in its entirety. Preservatives, stabilizers, dyes and evenflavoring agents may be provided in the therapeutic composition. Forexample, sodium benzoate, ascorbic acid and esters of p-hydroxybenzoicacid may be added as preservatives. In addition, antioxidants andsuspending agents may be used.

Compositions of the active ingredients may be formulated and used astablets, capsules, or elixirs for oral administration; suppositories forrectal administration; sterile solutions; patches for transdermaladministration, and sub-dermal deposits and the like. Suitableexcipients are, for example, water, saline, dextrose, mannitol, lactose,lecithin, albumin, sodium glutamate, cysteine hydrochloride, and thelike. If desired, absorption enhancing preparations (for example,liposomes), may be utilized.

The compositions provided herein can be in the form of a dry powder. Forexample the dry powder can be in the form a shake mix or included in acapsule. For example, a dry powder composition provided herein can bemixed with a liquid (for example, water) to form a solution or aqueousslurry that can be consumed by a user as a beverage. In some cases, adry powder composition provided herein can be packaged as a bulk productwith or without a measuring spoon, as a single serving packagecontaining an amount of a dry powder composition to be mixed with aliquid (for example, 4 ounces water, 6 ounces water, 8 ounces water, 12ounces water). In some cases, a dry powder composition provided hereinincludes between 0.1 weight percent and 2.0 weight percent of one ormore sweet potato extracts. In some cases, a dry powder compositionprovided herein includes between 5 weight percent and 85 weight percentprotein. In some cases, a dry powder composition provided hereinincludes between 5 weight percent and 35 weight percent soluble fiber.

The compositions provided herein can include one or more additionalingredients. For example, a composition provided herein can includeprotein, carbohydrates, soluble fiber, flavorants, artificialsweeteners, preservatives, fillers, thickeners, colorants, and any otherfood safe additive. In some embodiments, the composition can includesugar, natural and artificial flavors, dextrose, cellulose gum,sucralose, bamboo whole plant extract, guar gum, xanthan gum, citricacid, malic acid, or L-tartaric acid. In some cases, a compositionprovided herein can include one or more fillers or thickeners selectedfrom the following: a hydroxyl containing compound, a dextrin or dextrinderivative, carboxymethyl cellulose, hydroxypropyl cellulose,hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methylcellulose, calcium caseinate, konjac, collagen, inulin, casein, wheatgluten, carrageenan, alginates, propylene glycol alginate, xanthan,dextrin, pullulan, curdlan, gellan, locust bean gum, guar gum, tara gum,gum tragacanth, pectin, agar, zein, karaya, gelatin, psyllium seed,chitin, chitosan, gum acacia, polyvinyl pyrrolidone, polyethylene oxide,polyvinyl alcohol, or a combination thereof. In some cases, acomposition provided herein can include between 0 and 5 weight percentthickener(s). In some cases, a composition provided herein can besubstantially free of artificial colors, artificial flavors, andchemical preservatives.

The compositions provided herein can include one or more proteins. Insome cases, a composition provided herein can include between 5 and 25grams of protein (for example, about 10 grams of protein) per 8 fluidounces of a beverage or for 30 grams of a powdered composition providedherein. In some cases, a composition provided herein can be in apowdered form and include between 5 weight percent and 85 weight percentprotein(s) (for example, between 10 weight percent and 50 weightpercent, between 15 weigh percent and 35 weight percent, between 30weigh percent and 60 weight percent, or between 10 weight percent and 20weight percent). For example, a composition provided herein can includebetween 10 weight percent and 13 weight percent of soy protein, between8 weight percent and 10 weight percent whey protein concentration,and/or between 5 weight percent and 7 weight percent whey proteinisolate. Examples of proteins that can be included in a compositionprovided herein include dairy protein, soy protein, whey protein, or acombination thereof.

The compositions provided herein can be in the form of a beverage. Abeverage composition provided herein can include a solution and/or aslurry. The composition provided herein can include additionalingredients such as fillers, thickeners, proteins, creamers, sweeteners,flavorants, or a combination thereof. In some case, a composition caninclude between 5 to 25 grams of protein per serving. In some case, acomposition can include less than 10 grams of total fat per serving. Insome case, a composition can include less than 5 grams of sugars perserving. In some case, a composition can include less than 10 grams ofsoluble fiber per serving. In some cases, a serving can be 8 ounces of abeverage composition or an amount of dry powder composition intended tobe mixed with a liquid to form a single serving. For example, 8 ouncesof water could be combined with about 30 grams of a dry powdercomposition provided herein to form a beverage composition. In somecases, a container or package containing a dry powder compositionprovided herein can include a measuring scoop or spoon sized to measureout a single serving of a dry powder composition provided herein.

Therapeutic preparations for oral use can be obtained by combining theactive ingredients with solid excipient, optionally grinding a resultingmixture, and processing the mixture of granules, after adding suitableauxiliaries, if desired, to obtain tablets or dragee cores. Suitableexcipients are, in particular, fillers such as sugars, includinglactose, sucrose, mannitol, or sorbitol; cellulose preparations such as,for example, maize starch, wheat starch, rice starch, potato starch,gelatin, gum tragacanth, methyl cellulose,hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/orpolyvinylpyrrolidone (PVP). If desired, disintegrating agents may beadded, such as the cross-linked polyvinyl pyrrolidone, agar, or alginicacid or a salt thereof such as sodium alginate. Dragee cores areprovided with suitable coatings. For this purpose, concentrated sugarsolutions may be used, which may optionally contain gum arabic, talc,polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/ortitanium dioxide, lacquer solutions, and suitable organic solvents orsolvent mixtures. Dyestuffs or pigments may be added to the tablets ordragee coatings for identification or to characterize differentcombinations of active ingredient doses. For this purpose, concentratedsugar solutions may be used, which may optionally contain gum arabic,talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/ortitanium dioxide, lacquer solutions, and suitable organic solvents orsolvent mixtures. Dyestuffs or pigments may be added to the tablets ordragee coatings for identification or to characterize differentcombinations of active ingredient doses. Such formulations can be madeusing methods known in the art. See, for example, 5,726,181 (poorlywater soluble compounds); 5,707,641 (therapeutically active proteins orpeptides); U.S. Pat. No. 5,667,809 (lipophilic agents); 5,576,012(solubilizing polymeric agents); 5,707,615 (anti-viral formulations);U.S. Pat. No. 5,683,676 (particulate medicaments); U.S. Pat. No.5,654,286 (topical formulations); U.S. Pat. No. 5,688,529 (oralsuspensions); 5,445,829 (extended release formulations); U.S. Pat. No.5,653,987 (liquid formulations); 5,641,515 (controlled releaseformulations) and 5,601,845 (spheroid formulations); all of which areincorporated herein by reference in their entireties. The therapeuticcompositions may be manufactured in a manner that is itself known, forexample, by means of conventional mixing, dissolving, granulating,dragee-making, levitating, emulsifying, encapsulating, entrapping, orlyophilizing processes.

To formulate the dosage including one or more active ingredientsdisclosed herein, known surface active agents, excipients, smoothingagents, suspension agents and pharmaceutically acceptable film-formingsubstances and coating assistants, and the like may be used. Preferablyalcohols, esters, sulfated aliphatic alcohols, and the like may be usedas surface active agents; sucrose, glucose, lactose, starch,crystallized cellulose, mannitol, light anhydrous silicate, magnesiumaluminate, magnesium metasilicate aluminate, synthetic aluminumsilicate, calcium carbonate, sodium acid carbonate, calcium hydrogenphosphate, calcium carboxymethyl cellulose, and the like may be used asexcipients; magnesium stearate, talc, hardened oil and the like may beused as smoothing agents; coconut oil, olive oil, sesame oil, peanutoil, soya may be used as suspension agents or lubricants; celluloseacetate phthalate as a derivative of a carbohydrate such as cellulose orsugar, or methylacetate-methacrylate copolymer as a derivative ofpolyvinyl may be used as suspension agents; and plasticizers such asester phthalates and the like may be used as suspension agents. Inaddition to the foregoing ingredients, sweeteners, fragrances,colorants, preservatives and the like may be added to the administeredformulation of the compound of the present disclosure, particularly whenthe compound is to be administered orally.

Further disclosed herein are various therapeutic compositions well knownin the art for uses that include intraocular, intranasal, andintraauricular delivery. Therapeutic formulations include aqueousophthalmic solutions of the active ingredients in water-soluble form,such as eyedrops, or in gellan gum (Shedden et al., Clin. Ther.,23(3):440-50 (2001)) or hydrogels (Mayer et al., Ophthalmologica,210(2):101-3 (1996)); ophthalmic ointments; ophthalmic suspensions, suchas microparticulates, drug-containing small polymeric particles that aresuspended in a liquid carrier medium (Joshi, A., J. Ocul. Pharmacol.,10(1):29-45 (1994)), lipid-soluble formulations (Alm et al., Prog. Clin.Biol. Res., 312:447-58 (1989)), and microspheres (Mordenti, Toxicol.Sci., 52(1):101-6 (1999)); and ocular inserts. All of theabove-mentioned references are incorporated herein by reference in theirentireties. Such suitable therapeutic formulations are most often andpreferably formulated to be sterile, isotonic and buffered for stabilityand comfort. Therapeutic compositions may also include drops and spraysoften prepared to simulate in many respects nasal secretions to ensuremaintenance of normal ciliary action. As disclosed in Remington'sPharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa.(1990), which is incorporated herein by reference in its entirety, andwell-known to those skilled in the art, suitable formulations are mostoften and preferably isotonic, slightly buffered to maintain a pH of 5.5to 6.5, and most often and preferably include antimicrobialpreservatives and appropriate drug stabilizers. Therapeutic formulationsfor intraauricular delivery include suspensions and ointments fortopical application in the ear. Common solvents for such auralformulations include glycerin and water.

The compositions described herein may be administered by either oral ornon-oral pathways. When administered orally, compositions can beadministered in capsule, tablet, granule, spray, syrup, or other suchform. Compositions also may be brewed, as with a tea, or formed bydissolving a powdered composition into a fluid, typically water, fruitor vegetable juice, or milk. When administered non-orally, it can beadministered as an aqueous suspension, an oily preparation or the likeor as a drip, suppository, salve, ointment or the like, whenadministered topically, rectally, or vaginally, as deemed appropriate bythose of skill in the art.

In some embodiments, the compositions described herein are formulatedinto a single pill or tablet. In some embodiments, the pill or tablethas a mass from 10 mg to 2000 mg. In some embodiments, the pill ortablet has a mass from 100 mg to 1500 mg. In some embodiments, the pillor tablet has a mass from 500 mg to 1200 mg. In some embodiments, thepill or tablet has a mass from 800 mg to 1100 mg.

The compositions provided herein can include an artificial sweetener.For example, a composition provided herein can include a high intensitysweetener, such as saccharine, sucralose, aspartame, acesulfamepotassium, or combinations thereof. In some cases, a compositionprovided herein can be substantially free of hydrogenated or trans fats.In some cases, a composition provided herein can be substantially freeof corn syrup. In some cases, a composition provided herein can besubstantially free of artificial colors, artificial flavors, andchemical preservatives. In some cases, a composition provided herein canbe substantially free of vitamins or mineral fortification.

Methods of Administration

Some embodiments also encompass methods for making and for administeringthe disclosed compositions. Such disclosed methods include, amongothers, (a) administration through oral pathways, which administrationincludes administration in capsule, tablet, granule, spray, syrup, orother such forms, (b) administration topically, (c) administrationrectally, or (d) administration vaginally, as deemed appropriate bythose of skill in the art for bringing the compound of the disclosureinto contact with living tissue; and (e) administration via controlledreleased formulations, depot formulations. As further examples of suchmodes of administration and as further disclosure of modes ofadministration, disclosed herein are various methods for administrationof the disclosed compositions including modes of administration throughintraocular, intranasal, and intraauricular pathways.

The therapeutically effective amount of the ingredients disclosed hereinrequired as a dose will depend on the route of administration and thephysical characteristics of the specific human under consideration. Thedose can be tailored to achieve a desired effect, but will depend onsuch factors as weight, diet, concurrent medication and other factors,which those skilled in the medical arts will recognize.

In practicing the methods of the disclosure, the products orcompositions can be used alone or in combination with one another or incombination with other therapeutic or diagnostic agents. These productscan be utilized in vivo, ordinarily in a mammal, preferably in a human,or in vitro. In employing them in vivo, the products or compositions canbe administered to the mammal in a variety of ways, includingparenterally, intravenously, subcutaneously, intramuscularly,colonically, rectally, vaginally, nasally or intraperitoneally,employing a variety of dosage forms. Such methods may also be applied totesting chemical activity in vivo.

As will be readily apparent to one skilled in the art, the useful invivo dosage to be administered and the particular mode of administrationwill vary depending upon the age, weight and mammalian species treated,the particular ingredients employed, and the specific use for whichthese ingredients are employed. The determination of effective dosagelevels, that is the dosage levels necessary to achieve the desiredresult, can be accomplished by one skilled in the art using routinetherapeutic methods. Typically, human clinical applications of productsare commenced at lower dosage levels, with dosage level being increaseduntil the desired effect is achieved. Alternatively, acceptable in vitrostudies can be used to establish useful doses and routes ofadministration of the compositions identified by the present methodsusing established therapeutic methods. In non-human animal studies,applications of potential products are commenced at higher dosagelevels, with dosage being decreased until the desired effect is nolonger achieved or adverse side effects disappear.

The dosage of active ingredient(s) may range broadly, depending upon thedesired affects and the therapeutic indication. Typically, dosages ofactive ingredient(s) may be between about 10 microgram/kg and 100 mg/kgbody weight, preferably between about 100 microgram/kg and 10 mg/kg bodyweight. Alternatively dosages may be based and calculated upon thesurface area of the patient, as understood by those of skill in the art.Administration is preferably oral on a daily or twice daily basis.Administration may include four tablets taken by mouth daily. In someembodiments, tablets may be administered during a meal time. In someembodiments, two tablets may be administered during a meal. In someembodiments, two tablets may be administered at breakfast and two atlunch.

The exact formulation, route of administration and dosage can be chosenin view of the consumer's condition. See for example, Fingl et al., inThe Pharmacological Basis of Therapeutics, 1975, which is incorporatedherein by reference in its entirety. The magnitude of an administrateddose may vary with the severity of a particular medical or physicalcondition and the route of administration. The severity of a conditionmay, for example, be evaluated, in part, by standard prognosticevaluation methods. Further, the dose and perhaps dose frequency mayalso vary according to the age, body weight, and response of theindividual. A program comparable to that discussed above may be used inveterinary medicine.

The combined active ingredients in the compositions disclosed herein maybe orally or non-orally administered to a human patient in the amount ofabout 10 mg/day to about 1,000 mg/day of the total active ingredients,and more preferably about 50 mg/day to about 400 mg/day of the totalactive ingredients at, one time per day or in other embodiments, overtwo to about ten times per day. Nonetheless, as will be understood bythose of skill in the art, in certain situations it may be necessary toadminister the active ingredients disclosed herein in amounts thatexcess, or even far exceed, the above-stated, preferred dosage range totreat effectively and aggressively a desired condition orcharacteristic.

Ingredients disclosed herein can be evaluated for efficacy and toxicityusing known methods. For example, the toxicology of a particularcompound or ingredient, or of a subset of the compounds, sharing certainchemical moieties, may be established by determining in vitro toxicitytowards a cell line, such as a mammalian, and preferably a human, cellline. The results of such studies are often predictive of toxicity inanimals, such as mammals, or more specifically, humans. Alternatively,the toxicity of particular compounds or ingredients in an animal model,such as mice, rats, rabbits, or monkeys, may be determined using knownmethods. The efficacy of a particular compound may be established usingseveral recognized methods, such as in vitro methods, animal models, orhuman clinical trials. Recognized in vitro models exist for nearly everyclass of condition, including the conditions abated by the compounds oringredients disclosed herein, including obesity. Similarly, acceptableanimal models may be used to establish efficacy of chemicals to treatsuch conditions. When selecting a model to determine efficacy, theskilled artisan can be guided by the state of the art to choose anappropriate model, dose, and route of administration, and regime. Ofcourse, human clinical trials can also be used to determine the efficacyof a compound or ingredient in humans.

The active ingredients described above may be used alone or incombination with one another, or in combination with other therapeuticor diagnostic agents. These products can be utilized in vivo or invitro. The useful dosages and the most useful modes of administrationwill vary depending upon the age and weight of the consumer, theparticular ingredients employed, and the specific use for which theseingredients are employed.

Methods of Use

The compositions described herein may be used for increasing thebioavailability, absorption, distribution, metabolism, and/or excretionof quercetin. The compositions described herein may be used for thereduction of blood pressure and LDL cholesterol, or for the increase ofathletic performance. Thus, in some embodiments, the compositionsdescribed herein are administered to a human with elevated bloodpressure or elevated LDL cholesterol. In some embodiments, thecompositions described herein are administered to a human for increasingathletic performance.

The following non-limiting examples are meant to describe the preferredmethods of the invention using certain preferred embodiments of theinvention. Variations in the details of the particular methods employedand in the precise compositions obtained will undoubtedly be appreciatedby those of skill in the art.

EXAMPLES Example 1 Flavonoid Chewable Tablet Formulation

The following example demonstrates an exemplary embodiment of acomposition comprising a flavonoid, and formulated as a chewable tablet.

A flavonoid composition was prepared by combining the following activeingredients, in the listed amounts in Table 2:

TABLE 2 Flavonoid Chewable Tablet Composition Active Ingredientmilligrams % (w/w) Blueberry Extract 225  33.9% Caffeine 52.5  7.9%Vitamin C (as Ascorbic Acid) 83.33  12.6% Green Tea Extract 90  13.6%Omega-3 F30 Powder 100  15.1% Quercetin 52.6  7.9% Ascorbyl Palmitate 60 9.0% Total: 663.43 100.0%

The prepared flavonoid composition was then combined with the followingnon-active ingredients to prepare a chewable tablet: Domino Sugar DirectCompressible (Batory); Dextrose (Agglomerated); Flavor (Masking TypeN&A) FCI 58002155; Flavor (Nat. Birthday Cake) Carmi 25193; Flavor(FLAVOR SWEET A NATURAL FLAVOR)—FCI #40018125; Flavor (Vanilla N&A) GoldCoast #310119; Natural Bitterness Suppressor; Flavor (RASPBERRY—NAT &ART)—FCI #79028114; Natural Bamboo Silica; Sucralose; Flavor (BlueberryN&A)—FCI #12001135; Citric Acid Anhydrous; Flavor (Acai—N&A) FCI#10001154; DL-Malic Acid; and L-Tartaric Acid. The chewable tablet wasconfigured to be administered at a dosage of two chewable tablets perdose.

Example 2 Flavonoid Tablet Formulation

The following example demonstrates an exemplary embodiment of acomposition comprising a flavonoid, and formulated as a tablet.

A flavonoid composition was prepared by combining the following activeingredients, in the listed amounts in Table 3. The quantity of eachingredient was confirmed at four weeks and at twelve weeks.

TABLE 3 Flavonoid Tablet Composition mg/one mg/four Assay Method tablettablets Total Phenolics (gallic acid Folin-Ciocalteu 104.25 ± 1.4 417.0± 5.7 equivalent) assay Total Proanthocyanidin DMAC assay  15.1 ± 0.8 60.3 ± 3.1 (procyanidin B2 equivalent) Total Anthocyanins HPLC_(520 nm) 16.3 ± 1.0  65.2 ± 4.0 (cyaniding-3-glucoside (38.6 equivalent)aglycone) Epigallocatechin Gallate HPLC_(280 nm)  21.4 ± 1.3  85.6 ± 5.2(EGCG) Quercetin HPLC_(360 nm)  23.9 ± 2.1  95.6 ± 8.4 CaffeineHPLC_(280 nm)  24.8 ± 1.1  99.1 ± 4.4

The ingredients were combined to prepare a tablet. The tablet servingsize is four tablets, with the following per serving: 50 kilocalories,12 grams of carbohydrate (4% of daily value), 10 grams of sugars, 100 mgof vitamin C (as ascorbyl palmitate; 167% of daily value), 156 mg ofwild bilberry fruit extract (std. min. 25% total anthocyanins), 180 mggreen tea leaf extract, 100 mg of quercetin, 100 mg natural caffeine(from Coffea Arabica bean), and 200 mg NovoOmega® Omega-3 F30 powder(std. 30% omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoicacid)). Additional ingredients may include sugar, natural and artificialflavors, dextrose, cellulose gum, sucralose, bamboo whole plant extract,guar gum, xanthan gum, citric acid, malic acid, and L-tartaric acid. Thetablet more than doubles the normal flavonoid intake and provides a morediverse array of flavonoids than typical.

Alternative Flavonoid Formulations

Additional exemplary formulations and compositions are prepared bycombining the following ingredients, in the listed amounts in Table 4.The quantity of each ingredient was confirmed at zero weeks and 12 weekslater. Table 4 lists the quantity in mg for four tablets.

TABLE 4 Alternative Flavonoid Composition Component Method 0 weeks 12weeks Total Phenolics (gallic Folin-Ciocalteu   452 ± 20.0  533 ± 8.0acid equivalent) assay Total Anthocyanins HPLC_(520 nm) 64.3 ± 1.7 62.8± 2.8 (cyaniding-3-O- glucose equivalent) Quercetin HPLC_(360 nm)  104 ±6.2 97.6 ± 8.8 Total Flavan-3-ols HPLC_(280 nm)  184 ± 9.2   188 ± 10.8Epigallocatechin HPLC_(280 nm) 88.4 ± 4.5 84.4 ± 5.2 gallate (EGCG)Epicatechin (EC) HPLC_(280 nm) 22.0 ± 2.4 24.0 ± 0.8 Unknown flavan-olHPLC_(280 nm) 40.4 ± 2.4 43.6 ± 2.0 (EGCG equivalent) Epicatechingallate HPLC_(280 nm) 33.2 ± 0.8 35.2 ± 2.8 (ECG) Caffeine HPLC_(280 nm) 107 ± 6.8 98.6 ± 2.4

The ingredients were combined to prepare a tablet. The tablet servingsize is four tablets, with the following per serving: 50 kilocalories,12 grams of carbohydrate, 100 mg of vitamin C (as ascorbyl palmitate),bilberry fruit extract (std. min. 25% total anthocyanins), green tealeaf extract (50% EGCG), quercetin aglycone, 107 mg caffeine, 60 mgn3-PUFA (24 mg as docosahexaenoic acid and 36 mg as eicosapentaenoicacid), and 329 mg total flavonoids (aglycone form). Additionalingredients include sugar (dextrose), natural and artificial flavors,cellulose gum, sucralose, bamboo whole plant extract, guar gum, xanthangum, citric acid, malic acid, and L-tartaric acid.

Example 3 Influence of Ingesting a Flavonoid-Rich Supplement on theHuman Metabolome and Concentration of Urine Phenolics

The following example demonstrates the effects of ingesting aflavonoid-rich composition in overweight or obese subjects.

This study measures the effect of ingesting a flavonoid-rich supplementon various biomarkers in overweight/obese women during a 12-week period.The flavonoid-rich supplement contains a mixture of flavonoids includingquercetin, catechins from green tea extract, and anthocyanins fromblueberry extract, and other food components that facilitate flavonoidbioactivity including fish oil, caffeine, and vitamin C.

The primary objective of this study is to evaluate the effect ofingesting a flavonoid-rich supplement on total urine polyphenolconcentration and shifts in blood metabolites related to flavonoidintake in healthy but overweight/obese community-dwelling adults.Subjects in the flavonoid supplement group achieve high urine polyphenolconcentrations.

Secondary objectives are to determine related effects on measures ofinflammation and oxidative stress. Chemistry profiles and symptom logsare compared pre- and post-study between groups to confirm prior safetydata collected on human participants.

Subjects randomized to ingestion of the flavonoid-rich supplementcompared to placebo will experience an increase in total urinepolyphenols concentrations and shifts in blood metabolites related toincreased flavonoid metabolism. Secondarily, subjects ingesting theflavonoid-rich supplement will experience a decrease in systemicinflammation and oxidative stress.

The following details demonstrate the effect of ingesting aflavonoid-rich supplement on blood metabolite shifts and urine phenolicsduring a 12-week period in overweight and/or obese women.

The characteristics for the control (placebo) group and test group(flavonoid composition) are provided in Table 5.

TABLE 5 Subject Characteristics Flavonoid (N = 51) Placebo (N = 52) MeanSD Mean SD P-Value Age (yr) 50.3 11.2 50.3 14.0 0.986 Height (in) 63.92.0 64.5 2.5 0.199 Weight (lbs) 186 39.0 191 40.8 0.516 Body Mass Index32.1 6.6 32.5 7.1 0.759 Body Fat (%) 42.0 7.3 41.9 7.4 0.972 C-reactiveprotein 4.66 4.8 4.89 5.5 0.823 (mg/L) Glucose (mg/dL) 95.7 15.9 96.417.5 0.855

Subjects were administered a flavonoid composition as described inExample 2 (flavonoid tablet) or a placebo, with 4 tablets each day for a12-week period. Two tablets were administered at breakfast and twotablets were administered at lunch.

Prior to the study, subjects were asked to respond to a survey todetermine their symptoms or feelings during the previous 4-week period.At the end of the study, the subjects were asked to complete the samesurvey. As shown in Table 6, subject responses were generally identicalprior to and following the survey, indicating that the composition didnot result in side effects.

TABLE 6 Intensity of Symptoms Flavonoid Flavonoid at Placebo Placebo atSymptom pre-study 12 weeks pre-study 12 weeks Constipation 1.8 2.2 1.71.9 Heartburn 1.8  2.9* 1.7 1.8 Bloating 2.1 2.3 1.9 2.3 Diarrhea 1.72.0 1.2 2.0 Energy 6.1 6.3 5.8 6.1 Fever 1.0 1.0 1.1 1.0 Cough 1.6 1.31.7 1.7 Stuffy nose 2.4 1.8 2.1 2.1 Headache 2.6 2.3 2.5 2.7 Joint pain2.6 2.8 2.5 2.4 Back pain 2.3 2.3 2.1 2.3 Allergies 3.5 2.1 3.7 2.7Stress 4.9 5.1 4.9 4.7 Focus 7.0 6.5 7.6 7.2 Well-being 8.0 7.8 8.2 8.3Sleep 6.8 6.8 7.2 7.3 Intensity of symptoms scaled from to 12, with 1being none and 12 being very high. *P < 0.05 group difference in change,pre-study to 12-week.

In addition, the serum diagnostics chemistries showed no groupdifferences at 12 weeks, except for the level of SGTP, indicating thatliver, kidney, and overall metabolic health were not negatively affectedby treatments (Table 7).

TABLE 7 Serum Diagnostic Chemistries Serum Diagnostic Flavonoid PlaceboChemistry Variable Pre-Study 12-wk Pre-Study 12-wk P-Value Sodium(mEq/L) 139 139 139 139 0.177 Blood Urea 13.7 13.0 14.0 13.1 0.814Nitrogen (mg/dL) Creatinine (mg/dL) 0.73 0.74 0.74 0.74 0.974 Protein6.93 6.90 6.82 6.86 0.324 Albumin (g/dL) 4.11 4.13 4.11 4.13 0.352Bilirubin (mg/dL) 0.51 0.52 0.53 0.56 0.513 Alkaline 69.5 69.3 72.4 71.00.545 Phosphatase (IU/L) Alanine 20.3 17.8 17.1 17.1 0.010Aminotransferase (U/L) (SGPT) Calcium (mg/dL) 9.49 9.48 9.39 9.28 0.886

As depicted in FIGS. 5A-5D, subjects that were administered theflavonoid composition had elevated diet flavonoid intake, elevated dietEGCG, elevated diet anthocyanins, and elevated diet quercetin (flavonoidsubjects depicted on the left, and control subjects on the right).Furthermore, as shown in FIG. 6, total urinary phenolics increased withsubjects that were administered the flavonoid composition as compared tothe control (flavonoid subjects depicted on the left, and controlsubjects on the right).

The flavonoid tablets were analyzed for phenolic content at weeks 4 and12 of the study, and all ingredients were stable at pre-study values.The supplement increased total diet flavonoid intake by 181%, andprovided a more diverse cocktail of flavonoids (anthocyanins, EGCG,quercetin) than typically ingested. This increase in dietary flavonoidintake translates to a significant decrease in mortality over time.Urine phenolic measurements showed a significant 23% increase in theflavonoid compared to placebo group during the 12-week study(interaction effect, P=0.041). This increase translates to a significantdecrease in mortality over time. Flavonoid and placebo groups did notdiffer after the 12-week study in symptoms (except for small heartburneffect), or serum diagnostic chemistries, indicating that ingestion ofthe flavonoid composition vs. placebo is not related to adverseside-effects.

In summary, the flavonoid composition significantly increased totalflavonoid, favan-3-ol, flavonol, and anthocyanidin intake to levels 44%above the U.S. mean for this age and sex group, despite starting withbelow average baselines. In fact, the increase in these compositionsoccurred even when lower amounts of flavonoids were provided than inpreviously conducted studies, indicating an increased bioavailabilityand bioactivity of the formulations provided herein.

Example 4 Influence of Ingesting a Flavonoid-Rich Supplement on theHuman Metabolome and Concentration of Urine Phenolics

The following example demonstrates the effects of ingesting aflavonoid-rich composition in overweight or obese subjects.

Subjects were provided placebo or flavonoid formulation tablets (inparticular, the formulation described in Table 4) in overweight/obesewomen during a 12-week period. Individuals were invited to participateif they were non-smokers and free of heart disease, cancer, stroke,rheumatoid arthritis, and type I diabetes. The participants agreed toavoid non-steroidal anti-inflammatory drugs, dietary or herbalsupplements that had the potential to influence inflammation oroxidative stress, and maintain normal diet and physical activity habitsduring the 12-week study. Subjects could not be pregnant or planning tobe pregnant during the study, and not currently on a weight reducingplan or using weight loss medications. Participants recorded all foodand beverage intake as part of a food record intake.

Table 8 provides the results of pre-study and 12-week flavonoid intake,with the 12-week values including the flavonoid supplement. Table 8shows significant increases in anthocyanins (335%), flavan-3-ols (142%),flavonols (1,107%), EGCG (534%), and quercetin (1,661%) in the flavonoid(with supplement) compared to placebo. FIG. 8 shows that the totalflavonoid intake increased 217% in the flavonoid group as a result oftaking the supplement compared to placebo.

TABLE 8 Food Record Flavonoid Intake Flavonoid Placebo Pre-Study 12-wkPre-Study 12-wk P-Value Anthocyanins (mg) 13.2 ± 4.9   57.4 ± 5.1   8.4± 2.5  17.6 ± 5.6   <0.001 Flavan-3-ols (mg) 107 ± 20.8 259 ± 19.5 115 ±35.2 85.0 ± 21.9  <0.001 EGCG 15.7 ± 3.3   99.5 ± 3.1   17.3 ± 5.6  12.5 ± 3.5   <0.001 Flavonols (mg) 9.36 ± 1.0   113 ± 0.9  9.09 ± 1.55 113 ± 0.9  <0.001 Quercetin (mg) 6.19 ± 0.67  109 ± 0.5  5.55 ± 0.87 109 ± 0.5  <0.001 Flavanones (mg) 7.46 ± 1.79  6.76 ± 1.76  10.9 ± 2.75 4.05 ± 1.15   0.077 Isoflavones (mg) 0.01 ± 0.01  0.19 ± 0.18  0.01 ±0.01  0.02 ± 0.01   0.360 Flavones (mg) 0.47 ± 0.08  0.64 ± 0.08  0.42 ±0.08  0.67 ± 0.14   0.500 Vitamin C (mg) 71.7 ± 10.4  175 ± 8.7  64.6 ±7.4   64.6 ± 7.4   <0.001 Caffeine (mg) 148 ± 29.8 247 ± 30.0 123 ± 13.5125 ± 13.1  0.016

In addition, serum samples were obtained to determine the serumdiagnostic chemistries of subjects taking the flavonoid supplementcompared to the placebo group. Specifically, serum levels of C-reactiveprotein (CRP), cytokine, oxidized LDL (oxLDL), and ferric reducingability of plasma (FRAP) were determined. For CRP, high-sensitivity CRPwas measured using an LX-20 clinical analyzer. For cytokine, the totalplasma concentration of two cytokines was determined: monocytechemoattractant protein-1 (MCP-1) and IL-6. The concentrations weredetermined using an electrochemiluminescence based solid-phase sandwichimmunoassay. All samples and provided standards were analyzed induplicate, and the intra-assay CV was 7.5% for the two cytokinesmeasured. For oxLDL, the concentration was measuring using standardprotocols for a competitive ELISA kit. FRAP was determined using asingle electron transfer reaction, using water-soluble antioxidants inthe plasma to reduce ferric iron to ferrous form, detectable at 593 nm.The results are shown in Table 9. FIG. 9 shows the change in plasmacaffeine levels during 12 weeks of flavonoid or placebo supplementation.

TABLE 9 Serum Concentrations of CRP, Cytokine, oxLDL, and FRAP FlavonoidPlacebo Pre-Study 4-wk 12-wk Pre-Study 4-wk 12-wk P-Value CRP 4.66 ±0.7  4.82 ± 0.7  4.64 ± 0.7  4.89 ± 0.76 5.19 ± 0.8  5.00 ± 0.8  0.750(mg/L) IL-6 0.81 ± 0.1  0.88 ± 0.1  0.86 ± 0.1  0.96 ± 0.10 1.13 ± 0.1 0.95 ± 0.1  0.343 (pg/mL) MCP-1 142 ± 5.7  129 ± 5.7  127 ± 4.9  141 ±5.5  135 ± 6.0  129 ± 5.4  0.493 (pg/mL) oxLDL 55.0 ± 2.2  55.7 ± 2.3 55.1 ± 2.5  52.3 ± 2.3  52.2 ± 2.5  52.7 ± 2.2  0.969 (U/mL/ 1000) FRAP 495 ± 12.9  500 ± 11.7  513 ± 13.5  503 ± 12.2  492 ± 12.3  509 ± 15.20.243 (μmol/L)

In addition, the effects of the formulations on gut-derived phenolicswere measured using a global metabolomics platform. Recovery standardswere added prior to the first step in the extraction process for qualitycontrol purposes. To remove protein, dissociate small molecules bound toprotein or trapped in the precipitated protein matrix, and to recoverchemically diverse metabolites, proteins were precipitated with methanolunder vigorous shaking for two minutes followed by centrifugation.Metabolites were identified by automated comparison of the ion featuresin the experimental samples to a reference library of chemical standardentries that included retention time, molecular weight, preferredadducts, and in-source fragments as well as associated MS spectra andcurated by visual inspection for quality control. Identification ofknown chemical entities was based on comparison to metabolomics libraryentries of purified standards.

The metabolomics dataset included 729 compounds of known identity. Ofthese, 63 biochemicals exhibiting significant interaction effect(p<0.05) were identified, as listed in Table 10.

TABLE 10 Biochemicals identified by Metabolomics Dataset BiochemicalName Super Pathway p-value 2-aminobutyrate Amino Acid 0.03742-methylbutyrylcarnitine (C5) Amino Acid 0.01443-(3-hydroxyphenyl)propionate sulfate Amino Acid 0.0500alpha-ketobutyrate Amino Acid 0.0208 guanidinosuccinate Amino Acid0.0400 homoarginine Amino Acid 0.0122 hydantoin-5-propionic acid AminoAcid 0.0303 N-acetylalanine Amino Acid 0.0005 N-acetylaspartate (NAA)Amino Acid 0.0130 N-acetylcarnosine Amino Acid 0.0438 tiglylcarnitine(C5:1-DC) Amino Acid 0.0276 vanillactate Amino Acid 0.0126 bilirubin(Z,Z) Cofactors and 0.0332 Vitamins gulonate* Cofactors and 0.0316Vitamins retinol (Vitamin A) Cofactors and 0.0038 Vitamins1-arachidonoyl-GPI (20:4)* Lipid 0.0474 1-palmitoyl-2-arachidonoyl-GPCLipid 0.0257 (16:0/20:4n6) 1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)*Lipid 0.0369 1-palmitoyl-2-oleoyl-GPC (16:0/18:1) Lipid 0.04341-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)* Lipid 0.0119 1-palmitoyl-GPI(16:0) Lipid 0.0014 1-stearoyl-2-linoleoyl-GPI (18:0/18:2) Lipid 0.04471-stearoyl-GPI (18:0) Lipid 0.0053 2-aminooctanoate Lipid 0.01582-hydroxyoctanoate Lipid 0.0108 2-hydroxystearate Lipid 0.03132-palmitoyl-GPC (16:0)* Lipid 0.0358 2-stearoyl-GPE (18:0)* Lipid 0.00593-hydroxybutyrylcarnitine (1) Lipid 0.0341 3-hydroxydecanoate Lipid0.0468 3-hydroxyoctanoate Lipid 0.0080 3-hydroxysebacate Lipid 0.0183adipoylcarnitine (C6-DC) Lipid 0.0175 dihomo-linolenate (20:3n3 or n6)Lipid 0.0430 dihomo-linolenoyl-choline Lipid 0.0440 glycosyl ceramide(d18:1/23:1, d17:1/24:1)* Lipid 0.0309 glycosyl-N-stearoyl-sphingosine(d18:1/18:0) Lipid 0.0387 pimeloylcarnitine/3-methyladipoylcarnitineLipid 0.0076 (C7-DC) pregn steroid monosulfate* Lipid 0.0346pregnen-diol disulfate* Lipid 0.0432 sphingomyelin (d18:2/14:0,d18:1/14:1)* Lipid 0.0355 sphingomyelin (d18:2/23:0, d18:1/23:1, Lipid0.0360 d17:1/24:1)* suberoylcarnitine (C8-DC) Lipid 0.0326taurocholenate sulfate Lipid 0.0467 N1-methylinosine Nucleotide 0.0317N-acetylisoleucine Nucleotide 0.0107 gamma-glutamylglycine Peptide0.0429 N-acetyl-beta-alanine Peptide 0.0042 1,2,3-benzenetriol sulfate(2) Xenobiotics 0.0300 1,3,7-trimethylurate Xenobiotics 0.0037 1,3-dimethylurate Xenobiotics 0.0113 1,7-dimethylurate Xenobiotics 0.01091-methylurate Xenobiotics 0.0002 1-methylxanthine Xenobiotics 0.00513-methoxycatechol sulfate (1) Xenobiotics 0.01505-acetylamino-6-amino-3-methyluracil Xenobiotics 0.01605-acetylamino-6-formylamino- Xenobiotics 0.0226 3-methyluracil benzoateXenobiotics 0.0419 caffeine Xenobiotics 0.0061 ectoine Xenobiotics0.0134 erythritol Xenobiotics 0.0051 eugenol sulfate Xenobiotics 0.0049paraxanthine Xenobiotics 0.0021

Of the 63 biochemicals listed in Table 10, 29 are lipids, 15 arexenobiotics, 14 are amino acids or peptides, 3 are cofactors andvitamins, and 2 are nucleotides. Of the 29 lipids, 15 are lysolipids,phospholipids, sphingolipids, or ceramides, 11 are fatty acids, 2 aresteroids, and 1 is bile. Of the 15 xenobiotics, 9 are xanthines involvedwith caffeine metabolism, 2 are benzoates, 2 are food components, and 2are chemicals. Of the 3 cofactors and vitamins, 1 is involved withvitamin A metabolism, 1 with ascorbate metabolism, and 1 with hemoglobinmetabolism. At least three of the 63 biochemicals were gut-derivedphenolics. At least three gut-derived phenolics increased in theflavonoid compared to placebo group, including 1,2,3-benzenetriolsulfate, 3-methoxycatechol sulfate, and 3-(3-hydroxyphenyl)propanoicacid sulfate. FIGS. 10A-10C show increases gut-derived phenolics in theflavonoid versus placebo group for three specific phenolics:3-methoxycatechol sulfate (FIG. 10A; p=0.015);3-(3-hydroxyphenol)propanoic acid sulfate (FIG. 10B; p=0.050); and1,2,3-benzenetriol sulfate (FIG. 10C; p=0.030).

The terms “a,” “an,” “the” and similar referents used in the context ofdescribing the invention (especially in the context of the followingclaims) are to be construed to cover both the singular and the plural,unless otherwise indicated herein or clearly contradicted by context.Recitation of ranges of values herein is merely intended to serve as ashorthand method of referring individually to each separate valuefalling within the range. Unless otherwise indicated herein, eachindividual value is incorporated into the specification as if it wereindividually recited herein. All methods described herein can beperformed in any suitable order unless otherwise indicated herein orotherwise clearly contradicted by context. The use of any and allexamples, or exemplary language (for example, “such as”) provided hereinis intended merely to better illuminate the invention and does not posea limitation on the scope of the invention otherwise claimed. Nolanguage in the specification should be construed as indicating anynon-claimed element essential to the practice of the invention. Further,each of the references listed herein is hereby expressly incorporated byreference in its entirety.

It is contemplated that numerical values, as well as other values thatare recited herein are modified by the term “about”, whether expresslystated or inherently derived by the discussion of the presentdisclosure. As used herein, the term “about” defines the numericalboundaries of the modified values so as to include, but not be limitedto, tolerances and values up to, and including the numerical value somodified. That is, numerical values can include the actual value that isexpressly stated, as well as other values that are, or can be, thedecimal, fractional, or other multiple of the actual value indicated,and/or described in the disclosure.

Herein, the term “approximately” includes values±10%. In preferredembodiments the term “approximately” includes values±5%. In morepreferred embodiments the term “approximately” includes values±2%.

Groupings of alternative elements or embodiments of the inventiondisclosed herein are not to be construed as limitations. Each groupmember may be referred to and claimed individually or in any combinationwith other members of the group or other elements found herein. It isanticipated that one or more members of a group may be included in, ordeleted from, a group for reasons of convenience and/or patentability.When any such inclusion or deletion occurs, the specification is deemedto contain the group as modified thus fulfilling the written descriptionof all Markush groups used in the appended claims.

Certain embodiments of this disclosure are described herein, includingthe best mode known to the inventors for carrying out the disclosure. Ofcourse, variations on these described embodiments will become apparentto those of ordinary skill in the art upon reading the foregoingdescription. The inventor expects skilled artisans to employ suchvariations as appropriate, and the inventors intend for the disclosureto be practiced otherwise than specifically described herein.Accordingly, this invention includes all modifications and equivalentsof the subject matter recited in the claims appended hereto as permittedby applicable law. Moreover, any combination of the above-describedelements in all possible variations thereof is encompassed by thedisclosure unless otherwise indicated herein or otherwise clearlycontradicted by context.

1. A flavonoid composition, comprising: quercetin, the quercetinselected from the group consisting of aglycone quercetin, quercetinglycoside, and isoquercetin, the quercetin present in an amount of about7.9% to about 16% (w/w); green tea extract; blueberry anthocyanidins;caffeine; and omega 3 powder, wherein the flavonoid composition isformulated as a powder.
 2. The flavonoid composition of claim 1,comprising: 33.9% (w/w) Blueberry Extract; 7.9% (w/w) caffeine; 12.6%(w/w) vitamin C; 13.6% (w/w) green tea extract; 15.1% (w/w) omega-3;7.9% (w/w) quercetin; and 9.0% ascorbyl palmitate.
 3. The flavonoidcomposition of claim 1, wherein the flavonoid composition is formulatedfor administration to a subject two to four times each day.
 4. Theflavonoid composition of claim 1, wherein the flavonoid composition isformulated for administration in combination with an aqueouscarbohydrate source.
 5. The flavonoid composition of claim 1, whereinthe flavonoid composition is formulated at a pH of about 3 to about 4.6. The flavonoid composition of claim 1, further comprising abioavailability enhancing agent selected form the group consisting of acharge masking compound, a solubilizing compound, a reducing compound, astabilizing compound, a lubricating compound, an enteric coating, and apermeability enhancing compound.
 7. The flavonoid composition of claim1, further comprising a flavonoid selected from the list consisting ofkaempferol, myricetin, isorhamnetin, luteolin, apigenin, herperetin,naringenin, eriodictyol, catechins, epigallocatechins, theaflavins,cyaniding, delphinidin, malvidin, pelargonidin, peonidin, petunidin,daidzein, genistein, and glycitein.
 8. A flavonoid composition,comprising: quercetin, the quercetin selected from the group consistingof aglycone quercetin, quercetin glycoside, and isoquercetin, thequercetin present in an amount of about 7.9% to about 16% w/w; and asecond ingredient selected from the group consisting of green teaextract, blueberry anthocyanidins, caffeine and n3-polyunsaturated fattyacids (N3-PUFA).
 9. The flavonoid composition of claim 8, comprising:33.9% (w/w) Blueberry Extract; 7.9% (w/w) caffeine; 12.6% (w/w) vitaminC; 13.6% (w/w) green tea extract; 15.1% (w/w) omega-3; 7.9% (w/w)quercetin; and 9.0% ascorbyl palmitate.
 10. A method for improvinghealth or performance of a subject, comprising administering to thesubject an oral ingestible medicament comprising: a flavonoid comprisingquercetin present in an amount of about 7.9% to about 16% w/w; anantioxidant; an anthocyanidin; a stimulant; a lipid; ascorbic acid; anomega 3 fatty acid; and ascorbyl palmitate; wherein the oral ingestiblemedicament is a capsule, a chewable tablet, a stick pack, a gummy, apowder, or a sachet.
 11. The method of claim 10, wherein the performanceof the subject comprises improvement in one or more of athleticperformance, bone health, immune response, recovery time after exercise,oxidative stress, and energy.
 12. The method of claim 10, wherein adaily dose of medicament comprises about 10 to about 500 mg offlavonoid.
 13. The method of claim 10, wherein the oral ingestiblemedicament increases total urinary phenolic concentration, dietaryflavonoid intake, dietary anthocyanin, dietary EGCG, or dietaryquercetin.
 14. The method of claim 10, wherein the oral ingestiblemedicament reduces the risk of mortality, neurodegenerative diseases,weight gain, systemic inflammation, oxidative stress, diabetes,cardiovascular disease, hypertension, or acute respiratory illness. 15.The method of claim 10, wherein the oral ingestible medicament improvescolon health or colon microbiome.
 16. The method of claim 10, whereinthe disorder is heart disease, diabetes, hypertension, allergicreactions, asthma, arthritis, cancer, prostate diseases, and oxidativestress, or combinations thereof.
 17. A method of improving flavonoidbioavailability and bioactivity in a subject, comprising administering achewable tablet to the subject, wherein the chewable tablet comprises:vitamin C; wild bilberry fruit extract; green tea leaf extract;quercetin aglycone present in an amount of about 7.9% to about 16% w/w;caffeine; and omega 3 fatty acids, wherein the total flavonoid intake isincreased.
 18. A composition comprising wild bilberry fruit extract,green tea leaf extract, quercetin aglycone, and omega 3 fatty acids. 19.The composition of claim 5, wherein the wild bilberry fruit extract ispresent in an amount of about 156 mg, wherein the green tea leaf extractis present in an amount of about 180 mg, wherein the quercetin aglyconeis present in an amount of about 100 mg, and wherein the omega 3 fattyacids is present in an amount of about 200 mg.
 20. The composition ofclaim 5, further comprising vitamin C present in an amount of about 100mg and caffeine present in an amount of about 100 mg.